What is Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy?
Cytoreductive surgery (CRS) in combination with Hyperthermic intraperitoneal chemotherapy (HIPEC) is a state-of-the-art therapeutic method planned for some patients with cancers that have spread to the lining of the abdominal cavity, known as the peritoneum. This highly specialized method combines surgical removal of large visible tumors with the direct administration of heated chemotherapy within the abdomen to target microscopic cancer cells that might be present after surgery.
In contrast to traditional chemotherapy, which travels throughout the body, HIPEC transfers chemotherapy directly to the affected area at the time of surgery. The solution used for chemotherapy is lightly heated to increase its effectiveness and is then circulated throughout the abdominal cavity under controlled conditions. This allows for greater local drug concentrations while reducing systemic exposure.
CRS+HIPEC might be an option for carefully selected patients with peritoneal metastases emerging from colorectal, appendiceal, ovarian, gastric, and some of the rare abdominal cancers. Treatment planning needs in-depth examination by an experienced cross-functional team to ascertain the extent of disease, overall health status, and suitability for the procedure.
At Yashoda Hospitals, CRS+HIPEC is performed by specialized surgical oncology teams supported by state-of-the-art operating theatres, critical care facilities, and complete cancer care services. Every treatment plan is suited to the patient’s individual diagnosis, disease burden, and goals of the treatment.
The unified approach of CRS+HIPEC aims to improve disease control, decrease the risk of residual cancer within the abdominal cavity, and offer some patients an opportunity for better long-term results. With coordinated care from diagnosis through recovery and follow-up, CRS-HIPEC is a sign of great advancement in the management of complicated abdominal cancers.
Types Of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
CRS+HIPEC is a combination therapy instead of being a single procedure. It is normally categorized based on the underlying cancer type or treatment strategy.
- CRS+HIPEC for Colorectal Cancer: This method is used for some patients whose colorectal cancer has spread to the lining of the abdominal cavity. Cytoreductive surgery removes visible tumors, whereas HIPEC aims at removing microscopic cancer cells.
- CRS+HIPEC for Appendiceal Cancer: Mostly suggested for appendiceal tumors, including pseudomyxoma peritonei. This method assists in removing deposits of tumor and decreases the risk of disease recurrence within the abdomen.
- CRS+HIPEC for Ovarian Cancer: In some patients with state-of-the-art ovarian cancer, CRS+HIPEC might be used in addition to standard cancer treatments to improve disease control.
- CRS+HIPEC for Gastric Cancer: This therapy might benefit some selected patients with stomach cancer that has spread to the peritoneum, helping address both visible and microscopic disease.
- CRS+HIPEC for Peritoneal Mesothelioma: A specialized treatment option for cancers arising from the peritoneal lining, combining extensive tumor removal with heated chemotherapy for improved local treatment.
- CRS+HIPEC for pseudomyxoma peritonei (PMP): This combination is used to provide therapy for a rare condition characterized by mucus-producing tumors within the abdomen. The objective of the procedure is to remove accumulated tumor tissue and prevent further spread.
- Primary CRS+HIPEC: This procedure is performed as part of the initial treatment plan when the disease is considered suitable for surgical removal and intraperitoneal chemotherapy.
- Interval CRS+HIPEC: This is performed after a course of systemic chemotherapy to decrease the burden of the tumor and improve the effectiveness of the surgery.
- Repeat CRS+HIPEC: In carefully selected cases, the procedure might be repeated if peritoneal disease recurs after previous treatment.
- Curative-Intent CRS+HIPEC: This procedure is done when a complete or close to complete tumor removal is possible to achieve, to maximize long-term disease control and survival results.
| Procedure Name | Cytoreductive Surgery With HIPEC |
|---|---|
| Surgery type | An advanced cancer surgical procedure that aims at the removal of visible tumors from the abdominal cavity, followed by the circulation of heated chemotherapy directly within the abdomen to target microscopic cancer cells |
| Type of anesthesia used | General Anesthesia |
| Duration of procedure | Approximately 6 to 12 hours, depending on the extent of disease, number of organs involved, and complexity of tumor removal |
| Duration of recovery | Most patients need 2 weeks to 4 weeks for initial recovery and might gradually restart routine activities within 4 to 8 weeks. Complete recovery can take many months, depending on the extent of surgery, overall health, and post-operative progress |
Appointment
Second Opinion
Live Chat
Call
More
